International Clinical Trial: A single-center, Randomized, Double-blind, Placebo-controlled, Intervention Study to the Efficacy and Safety of 'VIXL03' in Subjects with Impaired Fasting Glucose

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (KCT0011364) titled 'A single-center, Randomized, Double-blind, Placebo-controlled, Intervention Study to the Efficacy and Safety of 'VIXL03' in Subjects with Impaired Fasting Glucose' on Dec. 22, 2025.

Study Type: Interventional Study

Study Design: Primary Purpose : Supportive Care, Intervention Model : Parallel, Blinding/Masking : Double, Blinding Target : Subject, Investigator, Allocation : RCT

Primary Sponsor: Bumin Hospital

Condition:

Endocrine, nutritional and metabolic diseases

Intervention: Dietary Supplement : Test group: Subjects will take two capsules of VIXL03 orally one daily for 12 weeks. Control group: Subjects will...